Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951808 · ClinicalTrials.gov registry record · NA
Preventing Acute Chest Syndrome by Transfusion Feasibility Study
A NA study, sponsored by Carelon Research.
- Completed
- Registry status
- NA
- Development phase
- 237
- Enrollment target
NCT00951808 is a NA study that has completed, run by Carelon Research. The registered enrollment target is 237 participants.
The verdict
NCT00951808, a NA study, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 237 participants
- Enrollment target
Study Summary
Acute chest syndrome (ACS) is similar to severe pneumonia and is a common cause of hospitalizations for people with sickle cell disease (SCD). Blood transfusions are one treatment option for ACS. High levels of an enzyme called secretory phospholipase A2 (sPLA2) may be present in people before they develop ACS. This study will determine how well sPLA2 levels can predict the onset of ACS and whether identifying high sPLA2 levels allows enough time to prevent ACS with blood transfusions. Results from this study will help to determine the feasibility of conducting a larger study that would further examine the use of sPLA2 levels and blood transfusions to prevent ACS in people with SCD.
Interventions
- BEHAVIORAL Standard care
- BIOLOGICAL Single blood transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951808
The ClinicalTrials.gov registry entry for NCT00951808 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard care is the first listed.
NCT00951808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00951808 about?
NCT00951808 is a clinical study titled "Preventing Acute Chest Syndrome by Transfusion Feasibility Study". Acute chest syndrome (ACS) is similar to severe pneumonia and is a common cause of hospitalizations for people with sickle cell disease (SCD). Blood transfusions are one treatment option for ACS. High levels of an enzyme called secretory phospholipase A2 (sPLA2) may be present in people before they ...
What is the current status of trial NCT00951808?
This trial is currently completed. It is a NA study. The enrollment target is 237 participants. The study started on 2009-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00951808?
The interventions under investigation include: Standard care (BEHAVIORAL), Single blood transfusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT00951808?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.